Clinical trial · Observational
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas: Large Single-Center Observational Cohort Study (GLIOTARG)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Astrocytoma | Anaplastic Astrocytoma | CURATED_BROADER | 0.80 |
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Pleomorphic Xanthoastrocytoma | Pleomorphic Xanthoastrocytoma | ONTOLOGY_EXACT | 0.90 |
| Recurrent Malignant Glioma | Malignant Glioma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab-Containing Regimens | Drug | — | UNRESOLVED |
| BRAF ± MEK Targeted Therapy | Drug | — | UNRESOLVED |
| Non-Bevacizumab Regimens | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Glioblastoma, IDH-wildtype
- description
- Patients with histologically and molecularly confirmed diagnosis of glioblastoma according to the WHO 2021 classification. Tumors are characterized by absence of IDH1/2 mutations (IDH-wildtype), WHO grade 4, and typically exhibit one or more of the following molecular features: TERT promoter mutation, EGFR gene amplification, +7/-10 chromosome copy-number changes. This cohort includes only de novo (primary) glioblastomas. Astrocytomas that have secondarily progressed to glioblastoma (IDH-mutant) were excluded
- interventionNames
- Drug: Bevacizumab-Containing Regimens
- Drug: Non-Bevacizumab Regimens
- Drug: BRAF ± MEK Targeted Therapy
- label
- Astrocytoma, IDH-mutant
- description
- Patients with histologically and molecularly confirmed diagnosis of astrocytoma according to the WHO 2021 classification. Tumors are characterized by presence of IDH1 or IDH2 mutations (IDH-mutant), WHO grade 3 or 4, and absence of 1p/19q codeletion. Grade 4 astrocytomas (formerly known as "IDH-mutant glioblastoma") additionally exhibit microvascular proliferation and/or necrosis.
- interventionNames
- Drug: Bevacizumab-Containing Regimens
- Drug: Non-Bevacizumab Regimens
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years at the time of initial brain tumor diagnosis; * Histologically confirmed diagnosis of malignant glioma, including: * Glioblastoma, IDH-wildtype (WHO grade 4) * Astrocytoma, IDH-mutant (WHO grade 3-4) * Pleomorphic xanthoastrocytoma (WHO grade 2-3) * Molecularly confirmed diagnosis according to WHO 2021 classification (with available data on IDH1/2, BRAF, 1p/19q, and MGMT status where applicable); * Documented disease recurrence or progression with available treatment-related data in medical records to assess at least one of the study outcome measures Exclusion Criteria: * Age \< 18 years at initial diagnosis; * Absence of molecular-genetic confirmation of the tumor (according to WHO 2021 classification); * Lack of documented disease recurrence or progression, or insufficient treatment-related data in medical records to assess at least one of the study outcome measures; * Prior participation in clinical trials with unblinded investigational agents where data cannot be extracted (except where data are available and verifiable); * Synchronous primary malignant neoplasms.
References
Publications (0)
Data not yet available